1. Obesity-Linked PPARγ S273 Phosphorylation Promotes Insulin Resistance through Growth Differentiation Factor 3.
- Author
-
Hall JA, Ramachandran D, Roh HC, DiSpirito JR, Belchior T, Zushin PH, Palmer C, Hong S, Mina AI, Liu B, Deng Z, Aryal P, Jacobs C, Tenen D, Brown CW, Charles JF, Shulman GI, Kahn BB, Tsai LTY, Rosen ED, Spiegelman BM, and Banks AS
- Subjects
- Alleles, Animals, Cells, Cultured, Growth Differentiation Factor 3 genetics, Humans, Insulin Resistance, Male, Mice, Mice, Inbred C57BL, Obesity metabolism, PPAR gamma genetics, Phosphorylation drug effects, Growth Differentiation Factor 3 metabolism, Obesity drug therapy, PPAR gamma metabolism, Thiazolidinediones pharmacology
- Abstract
The thiazolidinediones (TZDs) are ligands of PPARγ that improve insulin sensitivity, but their use is limited by significant side effects. Recently, we demonstrated a mechanism wherein TZDs improve insulin sensitivity distinct from receptor agonism and adipogenesis: reversal of obesity-linked phosphorylation of PPARγ at serine 273. However, the role of this modification hasn't been tested genetically. Here we demonstrate that mice encoding an allele of PPARγ that cannot be phosphorylated at S273 are protected from insulin resistance, without exhibiting differences in body weight or TZD-associated side effects. Indeed, hyperinsulinemic-euglycemic clamp experiments confirm insulin sensitivity. RNA-seq in these mice reveals reduced expression of Gdf3, a BMP family member. Ectopic expression of Gdf3 is sufficient to induce insulin resistance in lean, healthy mice. We find Gdf3 inhibits BMP signaling and insulin signaling in vitro. Together, these results highlight the diabetogenic role of PPARγ S273 phosphorylation and focus attention on a putative target, Gdf3., Competing Interests: Declaration of Interests E.D.R. is a paid consultant of Novartis. B.B.K. consults for Alterna and serves on the Scientific Advisory Board of Janssen Pharmaceuticals. A.S.B. and B.M.S. hold a patent related to this work., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF